Cargando…
P361: HIGH REMISSION AND SURVIVAL RATE IN ADULTS WITH MINIMAL RESIDUAL DISEASE-POSITIVE OR RELAPSED/REFRACTORY B-CELL ACUTE LYMPHOBLASTIC LEUKAEMIA TREATED WITH BLINATUMOMAB IN ROUTINE CLINICAL PRACTICE
Autores principales: | Chiaretti, Sabina, Blum, Sabine, Leguay, Thibaut, Balsat, Marie, Salek, Cyril, Fracchiolla, Nicola, Spyridonidis, Alexandros, Rijneveld, Anita, Papayannidis, Cristina, Ganzha, Sofia, Bhattacharyya, Reetabrata, Zugmaier, Gerhard, Pezzani Grueter, Isabella, Ochs, Andreas, Rambaldi, Alessandro |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Lippincott Williams & Wilkins
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10428485/ http://dx.doi.org/10.1097/01.HS9.0000968356.32331.0a |
Ejemplares similares
-
Real-world use of blinatumomab in adult patients with B-cell acute lymphoblastic leukemia in clinical practice: results from the NEUF study
por: Boissel, Nicolas, et al.
Publicado: (2023) -
Real-World Multicenter Experience in Tumor Debulking Prior to Blinatumomab Administration in Adult Patients With Relapsed/Refractory B-Cell Precursor Acute Lymphoblastic Leukemia
por: Bonifacio, Massimiliano, et al.
Publicado: (2022) -
Blinatumomab in Ph+ B-ALL: present and perspectives
por: Papayannidis, Cristina, et al.
Publicado: (2017) -
Blinatumomab vs historic standard‐of‐care treatment for minimal residual disease in adults with B‐cell precursor acute lymphoblastic leukaemia
por: Gökbuget, Nicola, et al.
Publicado: (2020) -
Improved survival and MRD remission with blinatumomab vs. chemotherapy in children with first high-risk relapse B-ALL
por: Locatelli, Franco, et al.
Publicado: (2022)